Zealand Pharma A/S

General Information

(Note: A Public offering: “Currently, our shares are traded on Nasdaq Copenhagen A/S, or Nasdaq Copenhagen, under the symbol “ZEAL” since 2010.“)

We are a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Our portfolio includes two approved products for the treatment of type 2 diabetes: (i) lixisenatide, which has been approved by the U.S. Food and Drug Administration, or FDA, and is marketed in the United States under the brand name Adlyxin and which has been approved by the European Medicines Agency, or EMA, and by other regulatory authorities outside the United States where it is marketed under the brand name Lyxumia, and (ii) a combination of lixisenatide with Lantus, the brand name of insulin glargine developed by Sanofi S.A., or Sanofi, which has been approved by the FDA and is marketed in the United States under the brand name Soliqua100/33, and has been approved by the EMA and launched in the Netherlands under the brand name Suliqua. Suliqua is expected to be launched in certain other European countries beginning in the second half of 2017. Both Adlyxin / Lyxumia and Soliquia 100/33 / Suliquia are marketed by Sanofi pursuant to a license agreement granting Sanofi commercialization rights of these products. See “—Material Contracts—Sanofi License Agreement for Lixisenatide.”

Employees: 118
Founded: 1997
Contact Information
Address Smedeland 36, 2600 Glostrup, Denmark
Phone Number +45 88 77 36 00
Web Address http://www.zealandpharma.com
View Prospectus: Zealand Pharma A/S
Financial Information
Market Cap $546.1mil
Revenues $48.5 mil (last 12 months)
Net Income $-32.6 mil (last 12 months)
IPO Profile
Symbol ZEAL
Exchange NASDAQ
Shares (millions): 4.4
Price range $17.87 - $17.87
Est. $ Volume $78.2 mil
Manager / Joint Managers Morgan Stanley/ Goldman Sachs
CO-Managers Guggenheim Securities/ Needham & Company
Expected To Trade: 8/9/2017
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change